Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Genfit   /   Genfit - 2023

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Laatste koers (eur) Verschil Volume
3,495   0,000   (0,00%) Dagrange 3,385 - 3,540 216.464   Gem. (3M) 336,3K

Genfit - 2023

Volgen
71 Posts
Pagina: «« 1 2 3 4 »» | Laatste | Omlaag ↓
  4. forum rang 10 DeZwarteRidder 20 september 2024 10:24
    GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
    September 19, 2024

    Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC)
    €59.0 million in revenues, including the €48.7 million milestone invoiced in June 2024
    Positive opinion from the European Medicines Agency Committee in July 2024, with final decision on marketing authorization for Iqirvo anticipated in the second half of 2024, clearing the path to an additional €26.5 million milestone payment expected upon Iqirvo’s pricing and reimbursement approval in three European countries

    Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); September 19, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half-year 2024 financial results and provided a corporate update.

    Pascal Prigent, CEO of GENFIT, commented:

    “The approval of Iqirvo in the United States was a very significant milestone for the entire GENFIT team. We are proud to have developed elafibranor from its initial discovery through late-stage trials and are thrilled to now see it prescribed to U.S. patients. We believe Iqirvo can potentially address a significant unmet need for people living with PBC. Following the positive CHMP opinion in July 2024, we also anticipate a final decision on authorization in Europe by the end of the year.”

    Mr. Prigent continued, “We believe the recent approval in the U.S. of Iqirvo demonstrates our robust drug development capabilities and, along with our strong financial position enabled by our partnership with Ipsen, we are well positioned to continue to develop innovative therapies for challenging and underserved liver conditions that are life-threatening.”

    I. 1H24 Business highlights1

    PBC

    Accelerated approval of Ipsen’s Iqirvo®2 (elafibranor) was granted on June 10, 2024 by the U.S. Food and Drug Administration (U.S. FDA), as a first-in-class treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

    Following Ipsen’s commercial launch in the U.S. in June 2024, first royalty invoicing began and a €48.7 million milestone payment was made.

    On July 25, 2024, Ipsen announced an “encouraging early start for Iqirvo in the U.S.” and indicated that “50% of Healthcare Professionals surveyed one week post launch were very likely to prescribe Iqirvo”. Ipsen also reported “early positive coverage determinations from commercial and government payer segments”3.

    On July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) issued a positive opinion for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA.
  5. Vileine 20 september 2024 10:25
    Gepubliceerd op Zone Beurs:

    de inkomsten bedroegen 58.973 duizend euro vergeleken met 11.482 duizend euro voor dezelfde periode in 2023.

    Voor de zes maanden eindigend op 30 juni 2024:

    € 48,7 miljoen is toe te schrijven aan een mijlpaal die in juni 2024 aan Ipsen werd gefactureerd na de eerste commerciële verkoop van Iqirvo/elafibranor in de Verenigde Staten.
    € 9,3 miljoen is toe te schrijven aan de gedeeltelijke opname van over te dragen opbrengsten zoals toegelicht in Toelichting 20 - "Uitgestelde opbrengsten en opbrengsten".
    € 0,2 miljoen is toe te schrijven aan royalty's op de verkoop van Iqirvo/elafibranor in de Verenigde Staten.
71 Posts
Pagina: «« 1 2 3 4 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee